Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China

Jiang, Yongpo; He, Susu; Zhang, Chao; Wang, Xiaodan; Chen, Xi; Jin, Yingying; He, Zhike; Cai, Minjie; Lin, Zongmei; Ying, Lingjun; Mou, Jianli; Zhao, Haihong; Lin, Ronghai; Zhang, Sheng; Wu, Xiaomai; Chen, Haixiao; Lv, Dongqing

doi:10.21037/atm.2020.04.20

Cited by 27 publications

(31 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, hospitals in Wuhan only accept patients who have been diagnosed as showing COVID-19, while hospitals outside Wuhan admitted many patients who were not diagnosed at admission and were also hospitalized for the 1-3 days it took for nucleic acid test results to arrive. Three studies from regions with sufficient medical resources [32][33][34], namely Taizhou, Guangdong, and Shenzhen, can support our hypotheses since their median hospital stays were 18 days, 20 days, and 20 days, respectively, which were close to the results of this study.…”

Section: Discussionsupporting

confidence: 88%

Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu District, Hubei Province: a single-center descriptive study

et al. 2020

View full text Add to dashboard Cite

Background: We aimed to report the epidemiological and clinical characteristics of hospitalized patients with coronavirus disease-19 (COVID-19) in Zengdu District, Hubei Province, China. Methods: Clinical data on COVID-19 inpatients in Zengdu Hospital from January 27 to March 11, 2020 were collected; this is a community hospital in an area surrounding Wuhan and supported by volunteer doctors. All hospitalized patients with COVID-19 were included in this study. The epidemiological findings, clinical features, laboratory findings, radiologic manifestations, and clinical outcomes of these patients were analyzed. The patients were followed up for clinical outcomes until March 22, 2020. Severe COVID-19 cases include severe and critical cases diagnosed according to the seventh edition of China's COVID-19 diagnostic guidelines. Severe and critical COVID-19 cases were diagnosed according to the seventh edition of China's COVID-19 diagnostic guidelines. Results: All hospitalized COVID-19 patients, 276 (median age: 51.0 years), were enrolled, including 262 non-severe and 14 severe patients. The proportion of patients aged over 60 years was higher in the severe group (78.6%) than in the non-severe group (18.7%, p < 0.01). Approximately a quarter of the patients (24.6%) had at least one comorbidity, such as hypertension, diabetes, or cancer, and the proportion of patients with comorbidities was higher in the severe group (85.7%) than in the non-severe group (21.4%, p < 0.01). Common symptoms included fever (82.2% [227/276]) and cough (78.0% [218/276]). 38.4% (106/276) of the patients had a fever at the time of admission. Most patients (94.9% [204/276]) were cured and discharged; 3.6% (10/276) deteriorated to a critical condition and were transferred to another hospital. The median COVID-19 treatment duration and hospital stay were 14.0 and 18.0 days, respectively.

show abstract

Section: Discussionsupporting

confidence: 88%

Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu District, Hubei Province: a single-center descriptive study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Then, 771 articles were removed after reading the title and abstract, and 142 were excluded from the remaining 319 articles for various reasons. In the end, 55 full-text studies involving 10014 COVID-19 patients were included in this meta-analysis based on the detailed assessment and inclusion criteria (Figure 1) [20,21,22,23,24,25,26,27,28,29,30], [31,32,33,34,35,36,37,38,39,40], [41,42,43,44,45,46,47,48,49,50] also found that most of these studies (n ¼ 49) were based in China, although three studies were identified from the USA, two studies were from Italy, and one study from South Korea was included. The quality of most included studies was of high quality (score ranges between 6-8) assessed by the Newcastle Ottawa scale.…”

Section: Study Selection and Quality Assessmentmentioning

confidence: 99%

“…Fever, cough, fatigue, anorexia, myalgia, dyspnea, chest tightness, sputum production, hemoptysis, pharyngalgia, diarrhea, nausea, vomiting, abdominal pain, headache, dizziness and sore throat were reported in 47,46,37,8,34,40,22,25,4,7,39,17,18,9,27, 10 and 13 studies, respectively. The percentages of these symptoms in severe and nonsevere COVID-19 cases are presented in Figure 3 and Table 2, and forest plots are presented in Figure 9.…”

Section: Effect Of Clinical Symptoms On the Disease Severitymentioning

confidence: 99%

Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: A meta-analysis with 55 studies and 10014 cases

Barek

Aziz

Islam

2020

Heliyon

175

117

View full text Add to dashboard Cite

Purpose Severe acute respiratory coronavirus 2 (SARS-CoV-2) cases are overgrowing globally and now become a pandemic. A meta-analysis was conducted to evaluate the impact of age, sex, comorbidities, and clinical characteristics on the severity of COVID-19 to help diagnose and evaluate the current outbreak in clinical decision-making. Methods PubMed, ScienceDirect, and BMC were searched to collect data about demographic, clinical characteristics, and comorbidities of COVID-19 patients. Meta-analysis was conducted with Review Manager 5.3. Publication bias was assessed using Egger's test and Begg-Mazumdar's rank correlation. Results Fifty-five studies were included in this meta-analysis, including 10014 patients with SARS-CoV-2 infection. Male cases and cases with an age of ≥50 years (OR = 2.41, p < 0.00001; RR = 3.36, p = 0.0002, respectively) were severely affected by SARS-CoV-2. Patients having age≥65 years are not associated (p = 0.110) with the severity of COVID-19. Presence of at least one comorbidity or hypertension, diabetes, cerebrovascular disease, cardiovascular diseases, respiratory disease, malignancy, chronic kidney disease and chronic liver diseases individually increased the severity of COVID-19 cases significantly (OR = 3.13, p < 0.00001; OR = 2.35, p < 0.00001; OR = 2.42, p < 0.00001; OR = 3.78, p < 0.00001; OR = 3.33, p < 0.00001; OR = 2.58, p < 0.00001; OR = 2.32, p < 0.00001; OR = 2.27, p = 0.0007; OR = 1.70, p = 0.003, respectively). Clinical manifestation such as fever, cough, fatigue, anorexia, dyspnea, chest tightness, hemoptysis, diarrhea and abdominal pain (OR = 1.68, p = 0.0001; OR = 1.41, p = 0.004; OR = 1.26, p = 0.03; OR = 2.38, p < 0.0001; OR = 4.30, p < 0.00001; OR = 2.11, p = 0.002; OR = 4.93, p < 0.0001; OR = 1.35, p = 0.03; OR = 2.38, p = 0.008, respectively) were significantly associated with the severity of cases. No association of severity was found with myalgia, pharyngalgia, nausea, vomiting, headache, dizziness and sore throat (p > 0.05). No publication bias was found in case of age (≥50 years, age≥65 years), comorbidities and clinical manifestations. Conclusions Males patients and elderly or older patients (age ≥50 years) are at higher risk of developing severity, whereas comorbidities and clinical manifestations could significantly affect the prognosis and severity of COVID-19.

show abstract

“…Patients with this disease commonly present with symptoms like fever, fatigue, dry cough, sore throat, and difficulty breathing [ 2 ]. A number of patients may also develop lymphopenia and pneumonia with characteristic findings on chest computed tomography (CT) [ 3 ]. Several clinical studies have identified comorbidities like hypertension, diabetes mellitus, chronic obstructive pulmonary disease, cardiovascular disease, and obesity as risk factors for worsening of outcomes with COVID-19 [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Does Asthma Increase the Mortality of Patients with COVID-19?: A Systematic Review and Meta-Analysis

Wang

Chen

et al. 2020

Int Arch Allergy Immunol

View full text Add to dashboard Cite

The purpose of this systematic review and meta-analysis was to explore the literature and collate data comparing the mortality of coronavirus disease 2019 (COVID-19) patients with and without asthma. The databases PubMed, Scopus, Embase, Google Scholar, and medRxiv.org were searched for studies comparing the clinical outcomes of asthmatic patients with those of nonasthmatic patients diagnosed with COVID-19. Mortality data were summarized using the Mantel-Haenszel OR with 95% CI in a random-effects model. Five retrospective studies met the inclusion criteria. A meta-analysis of data from 744 asthmatic patients and 8,151 nonasthmatic patients indicated that the presence of asthma had no significant effect on mortality (OR = 0.96; 95% CI 0.70–1.30; I 2 = 0%; p = 0.79). Results were stable in a sensitivity analysis. A descriptive analysis of other clinical outcomes indicated no difference in the duration of hospitalization and the risk of intensive care unit (ICU) transfer between asthmatic and nonasthmatic patients. To conclude, preliminary data indicates that asthma as a comorbidity may not increase the mortality of COVID-19. Data on the influence of asthma on the risk of hospitalization, the duration of hospitalization, the requirement of ICU admission, and disease severity is still too limited to draw any strong conclusions. Further studies with a larger sample size are required to establish strong evidence.

show abstract

Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China

Cited by 27 publications

References 16 publications

Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu District, Hubei Province: a single-center descriptive study

Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu District, Hubei Province: a single-center descriptive study

Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: A meta-analysis with 55 studies and 10014 cases

Does Asthma Increase the Mortality of Patients with COVID-19?: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About